Mouse Study Suggests Treatment Strategy Could Benefit Patients with Obesity
It’s bad enough that the excess abdominal fat carried by most individuals with obesity causes widespread inflammation throughout their bodies. To add insult to injury, that inflammation actually makes it harder to use up overloaded fat stores. However, a new IRP mouse study supports a two-pronged pharmaceutical approach that could break this vicious cycle and help improve the health of people with obesity.
IRP Researchers Discover Genetic Disorder Affecting the Brain and Skull
A baby is born with a birth defect every four and a half minutes in the United States, adding up to one in every 33 babies born each year in this country. While some birth defects can be corrected or treated, many result in life-altering disabilities, and sometimes the child doesn’t survive. In fact, birth defects account for about 20 percent of infant deaths in the U.S. World Birth Defects Day, celebrated on March 3 each year, honors the people and organizations who are working to understand, prevent, and treat birth defects.
One of these organizations is the Undiagnosed Diseases Program (UDP) at NIH, which connects experts across the IRP’s 23 Institutes and Centers in a joint effort to find explanations for the “most puzzling medical cases" referred to the NIH Clinical Center.
NIH History Office Highlights Contributions of Black Employees
Every February, we celebrate Black History Month to spotlight the huge contributions Black Americans have made to our nation’s culture, as well as commemorate their ongoing fight for fair treatment under the law. Just as Black individuals have had tremendous influence on the U.S. as a whole, they have also achieved great things at NIH, demonstrating the critical importance of diversity within the scientific community.
In honor of Black History Month, we’re highlighting people and programs that championed diversity at NIH. Read on to learn about just a few examples of how diversity has evolved at NIH and how Black employees have helped advance its mission.
Since the early days of the COVID-19 pandemic, IRP researchers have been hard at work learning about the virus and developing ways to prevent and treat infections. That research remains as important as ever, particularly as the new Omicron variant of the virus continues to spread rapidly.
Fortunately, NIH’s Intramural Targeted Anti-COVID-19 Program (ITAC) has been providing IRP scientists with millions of dollars to support their research on the pandemic virus, known as SARS-CoV-2. Last week, the “I Am Intramural” blog discussed ITAC-funded efforts to learn about the biology of the virus and how it affects the body. This week, we’ll look at IRP projects focused on ways to track, treat, and prevent infections.
It’s been more than two years since the first outbreak of COVID-19 occurred in China. During that time, amazing scientific advances have dramatically altered prevention and treatment for the illness, including the development of remarkably safe and effective vaccines. However, even with widespread vaccination, scientists predict that the disease will continue to circulate in society indefinitely, with seasonal ebbs and flows like the flu.
As a result, even as COVID-19 vaccine shots rolled out by the hundreds of millions, numerous IRP researchers continued studying the disease and the virus responsible for it. Many of these projects have been funded by the NIH’s Intramural Targeted Anti-COVID-19 Program (ITAC), an initiative that provides IRP researchers with funding for research related to COVID-19. Over the past year and a half, ITAC has provided more than $12 million to support a wide variety of projects — more than can be covered in just one blog post. Read on to learn about just a handful of the many ways IRP researchers are contributing to the fight against COVID-19, and stay tuned next week for another blog describing even more ITAC-funded COVID research.
Dr. Shameka Poetry Thomas Documents Black Women’s Experiences With Race and Racism
The numbers are clear: Black women are three to four times more likely to die from pregnancy-related causes than White women in the United States. However, the reasons why are less clear. By listening to patient’s stories, IRP postdoctoral fellow Shameka Thomas, Ph.D. hopes to pinpoint potential explanations for this racial health disparity.
“We are losing mothers and children because we are simply not listening,” Dr. Thomas says.
Trained as a medical sociologist at the University of Miami, Dr. Thomas has devoted her career to documenting the lived experiences of patients of color, particularly women, who are perceived as Black. Dr. Thomas contextualizes patient’s narratives within a framework of ‘street race,’ which refers to how a person’s racial identity is perceived by others, regardless of their self-reported racial identity. Examining the influence of street race on women’s healthcare experiences, she explains, allows researchers to determine how health disparities are influenced by “how others see you.”
Research in Cells Shows Promise for an Alternative Way to Halt Sperm Production
Birth control has long been mostly one-sided, as the vast majority of contraceptive methods are intended exclusively for women. However, recent IRP research has shown the potential of a new approach towards creating a reversible method of male contraception.
Women have a vast array of contraceptive options available to them, from ‘the pill’ to intrauterine devices (IUDs) and other products. However, for men, the only options aside from condoms are safe but irreversible surgical procedures. More than 40 percent of pregnancies in the U.S. are unintended, and additional options for male birth control could help reduce that number.
Early-Career Scientists Power Through Pandemic to Launch Labs
NIH has long prided itself on its ability to accelerate the careers of the brightest young physicians and scientists in the country. One of these many efforts is the Lasker Clinical Research Scholars Program, which provides a select group of individuals relatively early in their scientific careers with the funding and institutional support to start their own labs at NIH. After five to seven years of independent research in the IRP, Lasker Scholars are given the option to apply for three years of funding for work outside of NIH or to remain as investigators at NIH.
While launching a lab in the midst of a global pandemic is no easy task, five Lasker Scholars have done just that over the past year. Their research on cancer, Parkinson’s disease, childhood blindness, and inflammatory conditions is now well underway and promises to eventually improve the lives of many patients. Keep reading to learn more about how NIH’s newest Lasker Scholars are changing the way we treat those illnesses.
IRP Research Challenges Long-Held Ideas About Muscle Structure
It’s not every day an accidental observation overturns 100 years of biological knowledge. But that’s what happened when IRP Stadtman Investigator Brian Glancy, Ph.D., noticed something funny while reviewing high-definition 3D videos of muscle cells.
“To be honest, you could almost call this study an accident,” he says.
Dr. Glancy, who leads the National Heart, Lung, and Blood Institute (NHLBI)’s Muscle Energetics Lab, often uses the high-powered microscopes available through the NHLBI Electron Microscopy Core to study how energy is distributed through skeletal muscle cells — the ones that control voluntary movement — when they expand and contract.
Although he was focused on examining the cells’ energy-producing mitochondria, he could also see the other structures inside them, including the long, tube-like structures called myofibrils that are involved in muscle contraction. As he advanced the video and traveled down the length of the muscle, it looked to him like the myofibrils were changing shape.
Immune System Genes Linked to Severe Side Effects in Patients with Rare Disease
When you run the largest-ever study of a rare childhood disease, you become the go-to person when your peers notice something peculiar in patients with the illness. It was not too surprising, then, when a researcher from Stanford University in Palo Alto, California, asked IRP investigator Michael Ombrello, M.D., to help her team follow a new lead in the mystery of why some patients with a rare inflammatory condition called Still’s disease were coming down with a life-threatening lung ailment. The results of their collaboration could lead to a new precision medicine approach that individualizes therapy for Still’s disease based on patients’ DNA.
This page was last updated on Friday, January 14, 2022
